There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
Biogen is set for a revenue boost thanks to the approval of Alzheimers drug Leqembi. But other companies will also benefit ...
Approved by the FDA earlier this year, the Alzheimer's therapy lecanemab is an antibody that reduces the buildup in the brain of a sticky peptide called amyloid-beta (Aβ), which is thought to be ...
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease ...
Sep. 18, 2023 — A telecare program that improves outcomes for patients with dementia and lightens the load for unpaid caregivers also has the surprising bonus of cutting Medicare costs ...
The Food and Drug Administration is now regularly approving new drugs after just one or two clinical trials — a significant departure from the more rigorous vetting process the agency was ...
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Two new drugs from Eli Lilly—Leqembi and ...
An advisory committee to the U.S. Food and Drug Administration unanimously rejected a drug-and-device combination made by a Boston biotech, which the agency had already rejected twice.
The first Alzheimer’s therapy to clearly slow cognitive decline, approved in the United States last month, lifted the hope of patients and their families. But creating access to the program is a ...
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income ...
